Insmed Posts Quarterly Revenue of $524.4 Million Amid Unverified Acquisition Report
Key Facts
Reports on November 19 said Sanofi was interested in acquiring Insmed, but that interest and any consultation by the French company with advisers could not be verified. The report comes as Insmed posts rapid revenue growth and narrows its losses, making its operating performance an important part of the context. Insmed shares closed at $119.8 on November 18, according to EL7 data, the session before the report was published. Sanofi ADRs also closed at $47.12 that day. These prices do not represent either stock’s movement in the November 19 session.
Insmed said on October 29 that revenue totaled $524.4 million in the third quarter of 2026, versus $142.3 million in the same period a year earlier, an increase of 268%. Its net loss narrowed to $100.3 million, or $0.46 per share, from $370.0 million, or $1.75 per share, in the third quarter of 2025. The company raised the lower end of its 2026 revenue forecast for BRINSUPRI to $1.35 billion, while keeping the upper end at $1.4 billion, compared with a previous range starting at $1.25 billion and ending at $1.4 billion. It also raised its ARIKAYCE forecast to $460–470 million, from $450–470 million. Cash, cash equivalents and marketable securities totaled about $1.1 billion as of September 30, 2026.
The U.S. Food and Drug Administration approved BRINSUPRI on August 12, 2025, to treat non-cystic fibrosis bronchiectasis in adults and children aged 12 years and older. Insmed said when announcing the approval that the drug was the first and only treatment approved for the disease. The company estimated that about 500,000 people in the United States had been diagnosed with it. The approval and expanded commercial forecasts place BRINSUPRI in the context of the revenue growth Insmed reported in its quarterly results. These indicators do not, on their own, confirm acquisition interest from Sanofi.
A documented institutional link between the companies is Paul Hudson, whom Insmed appointed as an independent member of its board on October 20, 2026, alongside Utpal Koppikar. Hudson served as Sanofi’s chief executive from September 2019 until February 2026. His appointment provides context for the relationship between the two leadership teams, but does not establish that Sanofi is considering buying Insmed or has held talks about it. On the operating side, Sanofi posted total sales of 14.44 billion euros in the third quarter of 2026, up 14.3% at constant exchange rates, while Dupixent sales reached 5.69 billion euros.